Keisho Chìn

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.2K citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Least Two +8

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Medicine +7

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

Yasuhide Yamada, Katsuhiko Higuchi, Kazuhiro Nishikawa et al. · Annals of Oncology · 2014 · 524 citations · Full text

Chemotherapy-naïve Patients, Gastrointestinal Oncology, Advanced Gastric Cancer +8

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

Atsushi Ohtsu, Jaffer A. Ajani, Yu-Xian Bai et al. · Journal of Clinical Oncology · 2013 · 487 citations · Full text